Genuv Announces Preclinical Data To Be Released at Two Medical Conferences in June 2022

SEOUL, South Korea–(BUSINESS WIRE)– Genuv Inc.a clinical-stage biotechnology firm targeted on discovering revolutionary medication for degenerative central nervous system ailments and superior immuno-oncological therapies, introduced it’s going to launch new preclinical information at two main medical conferences in June.

“We’re excited to share new preclinical information for 2 of our drug candidates, SNR1611 and GNUV201,” mentioned Heung-rok Park, Ph.D., Genuv’s chief expertise officer.

Presentation particulars are proven under.

Keystone Symposium: Neurodegeneration: Organic Pathways Driving the Way forward for Therapeutic Improvement, June 5-9, Keystone, CO

Poster quantity: 1023
Title: Trametinib rescues neurodegeneration by TFEB-mediated activation of autophagic lysosomal operate in a mouse mannequin of Alzheimer’s Illness
Session: Poster session 1 on June 6, 2022
Presenter: Jenny Choih, KMD, Ph.D.

Poster quantity: 2022
Title: Trametinib prompts endogenous neurogenesis and restores the Alzheimer’s illness phenotype of 5XFAD
Session: Poster session 2 on June 7, 2022
Presenter: Jenny Choih, KMD, Ph.D.

Keystone Symposia abstracts can be found at https://www.keystonesymposia.org/conferences/view-abstracts.

ASCO 2022 Annual Assembly, June 3-7, McCormick Place, Chicago, IL

Summary quantity: e14509
Title: GNUV201, a novel cross-reactive human and mouse PD-1 monoclonal antibody for most cancers immunotherapy
Session: On-line publication

Abstracts might be launched by ASCO on Could 26, 2022, at 5 PM EDT at ASCO.org/abstracts.

ABOUT GENUV
Genuv Inc. is a frontrunner in drug discovery for central nervous system (CNS) problems and superior antibody remedy. ATRIVIEW^® The drug screening platform makes use of cell phenotypic evaluation and biomarkers to seek out substances for the event of neurodegenerative illness therapies. SHINE MOUSE firm^®NuvoFc^TM and NuvoMab^TM platform produces antibodies with superior affinity, solubility, and stability. Primarily based in Seoul, Korea, Genuv launched its first medical trial in Korea in 2020. Genuv makes use of scientific creativeness and distinctive platform expertise to handle challenges in debilitating ailments. Study extra at www.genuv.com.

About SNR1611
Discovered via our ATRIVIEW^® a drug screening platform, SNR1611 is a drug candidate that has been reused for neurodegenerative ailments from a beforehand FDA-approved anti-cancer drug. Genuv has confirmed the impact of SNR1611 on neuronal regeneration and useful restoration via preclinical research in animal fashions of Alzheimer’s and ALS. The event of SNR1611 was guided by our perception that neurodegenerative ailments will be handled with therapies that generate new neurons (“neurogenesis”), thereby inducing neural homeostasis. The Part 1/2a trial in sufferers with amyotrophic lateral sclerosis started in Korea in 2020, and the primary therapy arm is anticipated to be accomplished by the tip of 2022.

About GNUV201
GNUV201 is a brand new monoclonal anti-PD-1 antibody, developed through Genuv .’s SHINE MOUSE^® platform, a diversity-enhanced antibody discovery system. It displays extra selective binding traits within the low pH tumor microenvironment than within the regular impartial pH physiological atmosphere. Among the many many aggressive anti-PD-1 mAbs available on the market, GNUV201 is exclusive in its cross-reactivity in opposition to human and mouse PD-1 and by its superior binding affinity with slower Koff in comparison with Keytruda.^® and Opdivo^®. With its extraordinary properties in vitroit’s a promising candidate for brand new medication alone or for mixture remedy with current anti-cancer therapies for a number of sorts of strong tumors.

View supply model on businesswire.com: https://www.businesswire.com/information/residence/2220523006051/en/